Table 3 Genomic and protein description of mutations detected by Sanger and MinION sequencing
From: TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
Patient | Genomic description | Protein description | Exon/Intron | Functional Domain | Mutation frequencya | Raw Readsb | ALECc | Nanocorrectc |
|---|---|---|---|---|---|---|---|---|
CLL#2 | g.7577144A > G | p.Leu265Pro | 8-exon | DNA binding | 34 % | 38.6 % | 39.13 % | 78.72 % |
CLL#8 | g.7577548C > T | p.Gly245Ser | 7-exon | DNA binding | 31 % | 26.9 % | 30.28 % | ND |
CLL#10 | g.7577121_7577122GC > TT | p.Arg273Ser | 8-exon | DNA binding | 58 % | 41.5 % | 61.29 % | 93.55 % |
CLL#11 | g.7577501del | p.Ser261Valfsb84 | 7-exon | DNA binding | 46 % | 39.7 % | 44.21 % | 35.48 % |
CLL#12 | g.7578406C > T | p.Arg175His | 5-exon | DNA binding | ND | 18.3 % | 16.67 % | ND |